ArticleCell reports2022
Nasally delivered interferon-λ protects mice against infection by SARS-CoV-2 variants including Omicron.
Article in Cell reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The potential of IFN-λ, IL-32γ, IL-6, and IL-22 as safeguards against human viruses: a systematic review and a meta-analysis.Frontiers in immunology · 2024Pooled it
- Vaccination against influenza viruses reduces infection, not hospitalization or death, from respiratory COVID-19: A systematic review and meta-analysis.Journal of medical virology · 2024Pooled it
- Viral syncytia evolve to resist interferon.Nature communications · 2026Article
- The adult nasal mucosa is defined by distinct immune profiles that modulate in-vitro SARS-CoV-2 infection.Respiratory research · 2026Article
- The adult nasal mucosa is defined by distinct immune profiles that modulate in-vitro SARS-CoV-2 infection.Research square · 2026Article
- Computational Design and Glycoengineering of Interferon-Lambda for Nasal Prophylaxis Against Respiratory Viruses.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Differential antiviral effects and immune responses in nasal and airway organoid during RSV infection: implications for interferon therapy.Frontiers in immunology · 2026Article
- TLR7 deficiency enhances inflammation in the URT but reduces LRT immunity following influenza A infection.Scientific reports · 2025Article
- Intranasal Nanoliposomes Delivering Interferon Lambda with Enhanced Mucosal Retention as an Antiviral.Biomaterials research · 2025Article
- An ILC2-chitinase circuit restores lung homeostasis after epithelial injury.Science immunology · 2024Article
- Article
- Cell-intrinsic regulation of phagocyte function by interferon lambda during pulmonary viral, bacterial super-infection.PLoS pathogens · 2024Article
- Olfactory immunology: the missing piece in airway and CNS defence.Nature reviews. Immunology · 2024Review
- Interferon signaling in the nasal epithelium distinguishes among lethal and common cold coronaviruses and mediates viral clearance.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- IFN-λ uniquely promotes CD8 T cell immunity against SARS-CoV-2 relative to type I IFN.JCI insight · 2024Article
- Harnessing the power of IFN for therapeutic approaches to COVID-19.Journal of virology · 2024Review
- Article
- Heterogeneous SARS-CoV-2 kinetics due to variable timing and intensity of immune responses.JCI insight · 2024Article
- Diverging patterns in innate immunity against respiratory viruses during a lifetime: lessons from the young and the old.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- The antiviral state of the cell: lessons from SARS-CoV-2.Current opinion in immunology · 2024Review
Corrections and comments
- Update of
Authors and funding
9 authors.
Funding
Abstract
Although vaccines and monoclonal antibody countermeasures have reduced the morbidity and mortality associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, variants with constellations of mutations in the spike gene jeopardize their efficacy. Accordingly, antiviral interventions that are resistant to further virus evolution are needed. The host-derived cytokine interferon lambda (IFN-λ) has been proposed as a possible treatment based on studies in human coronavirus 2019 (COVID-19) patients. Here, we show that IFN-λ protects against SARS-CoV-2 B.1.351 (Beta) and B.1.1.529 (Omicron) variants in three strains of conventional and human ACE2 transgenic mice. Prophylaxis or therapy with nasally delivered IFN-λ2 limits infection of historical or variant SARS-CoV-2 strains in the upper and lower respiratory tracts without causing excessive inflammation. In the lung, IFN-λ is produced preferentially in epithelial cells and acts on radio-resistant cells to protect against SARS-CoV-2 infection. Thus, inhaled IFN-λ may have promise as a treatment for evolving SARS-CoV-2 variants that develop resistance to antibody-based countermeasures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.